Sep 12th 2013 - Edison Investment Research today published a report on Newron Pharmaceuticals SpA (NWRN.L, LSE:NWRN, LON:NWRN) entitled "Safinamide On Track". In summary, the report says:
Importantly, safinamide filings remain on track for Q413. Key pre-filing meetings with EU regulators have been completed. Feedback has not been disclosed, however we assume no major issues were raised given the reiterated filing timeline. Pre-filing meetings with the US FDA will be completed in coming weeks and feedback could help towards completing a US sub-licensing deal. Partnering safinamide in the US will be key to unlocking its full potential in Parkinson’s disease (PD).
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »